No Data
No Data
Maipu Medicine (301033): The collection pressure period has passed, and both domestic and overseas harvests have passed
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 231 million yuan (yoy +18.24%) and net profit of 41 million yuan (yoy+13).
Guoyuan Securities released a research report on April 25 stating that it gave Maipu Medical (301033.SZ) a purchase rating. The main reasons for the rating include: 1) rapid penetration of the craniomaxillofacial product group, accelerated release of new
Guoyuan Securities released a research report on April 25 stating that it gave Maipu Medical (301033.SZ) a purchase rating. The main reasons for the rating include: 1) rapid penetration of the craniomaxillofacial product group, accelerated release of new medical gel products; 2) active participation in collection, rapid channel expansion, and impressive international growth. (Mainichi Keizai Shimbun)
Commentary on Maipu Medical (301033) 2023 Report and 2024 First Quarter Report: Collection is expected to accelerate product penetration into new products and shine
Incident: Maipu Medical recently released reports for the first quarter of 2023 and 2024: in 2023, the company achieved revenue of 230 million yuan (+18.2%), net profit of 40 million yuan (+13.9%), net profit not returned to mother
Maipu Medical (301033): The company's new product launch is imminent, and the second growth curve is gradually becoming large-scale
Performance review The company released the 2023 annual report and the first quarter report of 2024. In 2023, the company achieved operating income of 231 million yuan, an increase of 18.24% over the previous year; achieved net profit attributable to the owner of the parent company of 0.41
Maipu Medical (301033.SZ) announced first-quarter results, net profit of 149.44,800 yuan, an increase of 91.19% year-on-year
Maipu Medical (301033.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved an operating income of 5...
Maipu Medical (301033.SZ): Achieving revenue of 231 million yuan in 2023, plans to distribute 10 to 4 yuan
Gelonghui, April 18 | Maipu Medical (301033.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 231 million yuan, an increase of 18.24%; net profit attributable to shareholders of listed companies was 408.774 million yuan, up 13.89% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 37.233 million yuan, an increase of 55.54% year on year; basic earnings per share of 0.62 yuan; it plans to distribute a cash dividend of 4.00 yuan (tax included) to all shareholders for every 10 shares.
No Data